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JAAD ONLINE: NOTES &
Commentary on: ‘‘Oxybenzone and
pregnancy: Time for more research
and patient education’’
To the Editor: We read with interest Drs Viola and
Grant-Kels’ letter1 discussing the potential risk of
oxybenzone in pregnancy, which advocates for
further high-quality safety studies for sunscreens
containing organic filters.
We agree that more research is warranted. As
highlighted by a 2020 Food & Drug Administration
(FDA) study, systemic absorption of oxybenzone
and other organic UV filters surpasses the maximum
threshold for waiving additional safety studies.2
It is important to note that, thus far, no known
significant detrimental effects to overall human
health have been identified from sunscreens despite
decades of use. Indeed, while some organic sunscreens (eg, oxybenzone and octinoxate) have been
identified as potential endocrine disruptors in vitro
and in animal models, a review by Suh et al,3
including search terms for pregnancy, highlights
that current evidence is mixed and thus not sufficient
to support a causal relationship between systemic
absorption and adverse health outcomes.
In the case of Hirschsprung disease, it is important
to emphasize that causation remains unknown
especially given that the in vivo association was
made using a single spot urine BP-3 collected at an
unspecified time after pregnancy, and the proposed
pathogenic mechanisms were based on in vitro
studies.1 Hirschsprung disease is exceedingly rare,
with a recent 20-year epidemiologic study in
California citing a stable incidence of 2.2 per 10,000
births with a higher incidence in individuals with
skin of color ( per 10,000 births, 4.05 in African
Americans, 2.45 in Asians, and 1.89 in Caucasians),4 a
demographic with traditionally lower sunscreen usage. Notably, these rates were similar to earlier US
cohorts examining the incidence dating back to the
1970s.
With the FDA’s recently released proposed
administrative order calling for additional safety
data for 12 of the organic filters, including oxybenzone, better characterization of risks to human
health should be more forthcoming.5 For those
looking to minimize unclear risks while awaiting
further study, sunscreens with inorganic filters, as
proposed by Viola and Grant-Kels, would be reasonable options. Of note, inorganic UV filters (ie,

J AM ACAD DERMATOL

COMMENTS

titanium dioxide and zinc oxide) have been proposed to be categorized by the FDA as generally
recognized as safe and effective. However, for those
who prefer the cosmetic elegance of organic sunscreens, discussion of potential, as yet unclear risks
versus the known benefit of photoprotection from
sunscreens will remain important in photoprotection
counseling.
Michael C. Kwa, MD, and Henry W. Lim, MD
From the Department of Dermatology, Henry Ford
Health System, Detroit, Michigan.
Funding sources: None.
IRB approval status: Not applicable.
Key words: photoprotection; pregnancy; sunscreen.
Reprints not available from the authors.
Correspondence to: Henry W. Lim, MD, Dermatology,
Henry Ford Medical Center—New Center One,
3031 West Grand Blvd, Suite 800, Detroit, MI
48202
E-mail: hlim1@hfhs.org
Conflicts of interest

Dr Lim is an investigator for Incyte, L’Oreal, Pfizer, and
PCORI. He has served as a consultant for Pierre Fabre,
ISDIN, Ferndale, La Roche-Posay, Cantabria, and
Beiersdorf. He has also participated as a speaker in general
educational sessions for La Roche-Posay and Cantabria
Labs. Dr Kwa has no conflicts of interest to declare.
REFERENCES
1. Viola KV, Grant-Kels JM. Oxybenzone and pregnancy: time for
more research and patient education. J Am Acad Dermatol.
2021. https://doi.org/10.1016/j.jaad.2021.11.049
2. Matta MK, Florian J, Zusterzeel R, et al. Effect of sunscreen
application on plasma concentration of sunscreen active
ingredients: a randomized clinical trial. JAMA. 2020;323(3):
256-267.
3. Suh S, Pham C, Smith J, Mesinkovska NA. The banned
sunscreen ingredients and their impact on human health: a
systematic review. Int J Dermatol. 2020;59(9):1033-1042.
4. Anderson JE, Vanover MA, Saadai P, Stark RA, Stephenson JT,
Hirose S. Epidemiology of Hirschsprung disease in California
from 1995 to 2013. Pediatr Surg Int. 2018;34(12):1299-1303.
5. Lim HW, Mohammad TF, Wang SQ. Food and Drug Administration’s proposed sunscreen final administrative order: how
does it affect sunscreens in the United States? J Am Acad
Dermatol. 2021. https://doi.org/10.1016/j.jaad.2021.09.052
https://doi.org/10.1016/j.jaad.2021.12.011

n 2021 e1

